title: Delisheng Injection (), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3.
abstract: OBJECTIVE
  To investigate the effect of Delisheng Injection (, DLS), a Chinese medicinal compound, DLS combined with cis-platinum (DDP), an active agent used in lung cancer chemotherapy, on a human highly metastatic giant lung carcinoma cell line PGCL3.
  
  
  METHODS
  The suspended PGCL3 cells at 10(5) /mL cultured in 96-well tissue culture plates were divided into 4 groups: DLS treatment group (2 μL/mL, 5 μL/mL, 10 μL/mL, 25 μL/mL), DDP treatment group (1 μg/mL, 2 μg/mL, 5 μg/mL, 15 μg/mL), combined DLS with DDP treatment group (DLS:DDP 2 μL/mL:1 μg/mL, 5 μL/mL:2 μg/mL, 10 μL/mL:5 μg/mL, 25 μL/mL:15 μg/mL) and a control group. The cytotoxicity of DLS with different concentrations (2 μL/mL, 5 μL/mL, 10 μL/mL, 25 μL/mL) on PGCL3 cells was determined by 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay. Effect of DLS on adhesion of PGCL-3 cells was tested by cell-matrigel adhesion assay. Chemotactic movement model of transwell camerula was used to determine the effect of DLS on invasion and migration of PGCL-3 cells.
  
  
  RESULTS
  Compared with the control group, DLS (2 μL/mL, 5 μL/mL, 10 μL/mL, 25 μL/mL) could significantly decrease cell proliferation, adhesion, invasion and migration abilities (P <0.05). Cell adhesion, invasion and migration abilities were significantly decreased after combination treatment of DLS:DDP (2 μL/mL:1 μg/mL, 5 μL/mL:2 μg/mL, 10 μL/mL:5 μg/mL, 25 μL/mL:15 μg/mL) compared with DDP single-agent treatment (1 μg/mL, 2 μg/mL, 5 μg/mL, 15 μg/mL, P<0.05), respectively.
  
  
  CONCLUSIONS
  DLS single-agent has a satisfying inhibition effect in PGCL3 cell line and DLS might enhance the inhibition effect of DDP on cancer metastasis. Our research provided a experimental basis about the treatment on highly metastatic lung caner.
authors.affiliation: Department of Respiratory, the Second Affiliated Hospital, College of Medicine of Xi'an Jiaotong University, Xi'an, 710004, China. dxl1103@163.com.
authors.forename: Xi-lin
authors.initials: XL
authors.lastname: Dong
authors.affiliation: Department of Pharmacy, the Fourth People's, Hospital of Ji'nan City, Ji'nan, 250031, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Gong
authors.affiliation: Department of Respiratory, Zibo Central Hospital, Zibo, Shandong Province, 255036, China.
authors.forename: Zhen-zhen
authors.initials: ZZ
authors.lastname: Chen
authors.affiliation: Department of Respiratory, the Second Affiliated Hospital, College of Medicine of Xi'an Jiaotong University, Xi'an, 710004, China.
authors.forename: Ya-juan
authors.initials: YJ
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage*; D004357:Drug Synergism; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008516:Medicine, Chinese Traditional; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis
chemical_list: D000970:Antineoplastic Agents; D004365:Drugs, Chinese Herbal; C524902:delisheng; D002945:Cisplatin
keywords: PGCL3; cis-platinum; delisheng; lung cancer